Provided by Tiger Fintech (Singapore) Pte. Ltd.

InflaRx N.V.

0.8024
-0.0086-1.06%
Post-market: 0.7938-0.0086-1.07%16:39 EDT
Volume:56.88K
Turnover:45.61K
Market Cap:54.36M
PE:-1.00
High:0.8143
Open:0.8130
Low:0.8000
Close:0.8110
Loading ...

InflaRx NV Appoints KPMG as New Auditor for 2025, Replacing EY

Reuters
·
28 Jun

InflaRx Is Maintained at Outperform by Oppenheimer

Dow Jones
·
30 May

InflaRx (IFRX) Gets a Buy from Oppenheimer

TIPRANKS
·
29 May

Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13

MT Newswires Live
·
29 May

InflaRx Nv : Raymond James Cuts to Outperform From Strong Buy; Cuts Target Price to $2 From $13

THOMSON REUTERS
·
29 May

Top Midday Decliners

MT Newswires Live
·
29 May

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast

Benzinga
·
29 May

InflaRx Stock (IFRX) Plummets 55% on Clinical Failure

TIPRANKS
·
28 May

InflaRx Nv : Leerink Partners Cuts Target Price to $2 From $5

THOMSON REUTERS
·
28 May

InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell

MT Newswires Live
·
28 May

Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX), Treace Medical Concepts (TMCI) and Amarin (AMRN)

TIPRANKS
·
12 May

InflaRx Initiated at Outperform by Oppenheimer

Dow Jones
·
08 May

InflaRx NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

InflaRx Q1 EPS $(0.14) Beats $(0.19) Estimate

Benzinga
·
07 May

InflaRx NV expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
05 May

InflaRx to Report First Quarter 2025 Results on May 7, 2025

GlobeNewswire
·
30 Apr

InflaRx Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
29 Apr

InflaRx N.V. Announces 2025 Annual General Meeting Agenda

TIPRANKS
·
03 Apr

InflaRx Is Maintained at Buy by Guggenheim

Dow Jones
·
26 Mar

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
26 Mar